Hims & Hers is achieving tremendous revenue growth with a renewed Novo Nordisk weight loss partnership. Click here to read an ...

The stock boasts the one year return of 34.3%, in contrast to 16.4% for the S&P 500. This situation necessitates a ...

HIMS deepens its AI and data strategy with personalized care tools, biomarker tracking, and smarter treatment matching.

Hims & Hers Health (NYSE: HIMS) went public in January 2021 through a SPAC merger, positioning itself as a multi-specialty ...

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Maple Tree Capital, an investment management company, released its Q3 2025 investor letter. A copy of the letter can be ...

Citi believes Novo Nordisk’s (NVO) announcement this morning that its Wegovy weight loss pill is now broadly available throughout the U.S. will ...

A short squeeze occurs when a stock's price rises unexpectedly, forcing short sellers (who are now losing money) to ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3.0 and $105.0 for Hims & Hers Health, spanning the last three ...

Not every Valley real estate deal comes with pomp and circumstance. This huge industrial transaction involving a national ...

Hims & Hers and Teladoc Health are expanding virtual care in different ways, but which telehealth platform looks more compelling right now? Let's dive in.